Rule 4.7B

Appendix 4C

Twelve Month report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Genesis Biomedical Limited

ABN

48 083 274 024

Twelve Month period ending

June 2005

Consolidated statement of cash flows

	Cash flows related to operating activities	Current month (June 2005) $A'000	Year to date (12 months) $A'000
1.1	Receipts from customers		
1.2	Payments for (a) staff costs		(60)
	(b) advertising and marketing		
	(c) research and development		
	(d) leased assets		
	(e) other working capital	(35)	(400)
1.3	Dividends received		
1.4	Interest and other items of a similar nature received	8	46
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Other (provide details if material)		
	Net operating cash flows	(27)	(414)

+ See chapter 19 for defined terms.

		Current month (June) $A'000	Year to date (12 months) $A'000
1.8	Net operating cash flows (carried forward)	(27)	(414)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses (item 5)		
	(b) equity investments		
	(c) intellectual property		
	(d) physical non-current assets		
	(e) other non-current assets		
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)		
	(b) equity investments		29
	(c) intellectual property		
	(d) physical non-current assets		
	(e) other non-current assets		
1.11	Loans to other entities		
1.12	Loans repaid by other entities		
1.13	Other (provide details if material)		
	Net investing cash flows	0	29
1.14	**Total operating and investing cash flows**	(27)	(385)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	0	300
1.16	Proceeds from sale of forfeited shares		
1.17	Proceeds from borrowings		
1.18	Repayment of borrowings		
1.19	Dividends paid		
1.20	Part refund of property lease security deposit	61	61
	Net financing cash flows	61	361
	Net increase (decrease) in cash held	34	(24)
1.21	Cash at beginning of month/year to date	1,030	1,088
1.22	Exchange rate adjustments to item 1.20		
1.23	**Cash at end of month/YTD**	1,064	1,064

*** The Company also had approximately $135,000 in security deposits which have not been included in the cash at the end of the periods.**

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current month (June) $A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	9
1.25	Aggregate amount of loans to the parties included in item 1.11	

1.26 Explanation necessary for an understanding of the transactions

$9k Being re-imbursement of travel expenses to Dr Robert Gilmour. (Non Exec Director Fees for June quarter $20k, Consulting Fees relating to Dr Robert Gilmour up to 30 June 05 for $30k and Company Secretary Fees of $12k for two months to 30 June 05 have all been accrued as at 30 June 05.)

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available $A'000	Amount used $A'000
3.1	Loan facilities		
3.2	Credit standby arrangements		

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current $A'000	Previous period $A'000
4.1	Cash on hand and at bank	62	35
4.2	Deposits at call	1,002	995
4.3	Bank overdraft		
4.4	Other (provide details)		
	Total: cash at end of quarter (item 1.22)	1,064	1,030

Acquisitions and disposals of business entities

		Acquisitions *(Item 1.9(a))*	Disposals *(Item 1.10(a))*
5.1	Name of entity		
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does give a true and fair view of the matters disclosed.

Sign here: Hartwig Date: ....14/07/05.......................

Print name: ..Shane Hartwig...

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.

   - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
   - 9.2 - itemised disclosure relating to acquisitions
   - 9.4 - itemised disclosure relating to disposals
   - 12.1(a) - policy for classification of cash items
   - 12.3 - disclosure of restrictions on use of cash
   - 13.1 - comparative information

3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.